Are changes in salivary secretion after taking vonoprazan linked to treatment-resistant gastroesophageal reflux disease?
- Conditions
- gastroesophageal reflux disease
- Registration Number
- JPRN-UMIN000053282
- Lead Sponsor
- ippon Medical School, Graduate School of Medicine.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Not provided
1. Take medication that can influence the secretion of saliva, such as antiadrenergic agents and adrenergic alpha-2 agonists, antidepressants, psychotropic drugs, anticholinergic drugs, and smokers in the last two weeks before enrollment. 2. Take medication that affects the secretion of gastric acid, such as PPI, PCAB, and histamine H2 receptor antagonists in the last two weeks before enrollment. 3. Have scleroderma and Sjogren syndrome that can affect esophageal motility and saliva secretion. 4. Have current peptic ulcers. 5. Have an upper gastrointestinal surgery 6. Have severe complications such as heart disease or cancer. 7. Have an allergy to xylocaine. 8. Have an allergy to vonoprazan. 9. pregnant or lactating 10. Have an oral environment in which gum chewing is likely to cause dental problems, such as caries or unstable teeth
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in salivary secretion after PCAB administration in PCAB-responsive patients.
- Secondary Outcome Measures
Name Time Method